Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial
OncoTargets and therapy, Volume 11, 2018, Pages 8575-8587.
Chinese patientsEGFRNSCLCPhase IIIafatinibMore(1+)
The findings support the rationale for using afatinib as a first-line treatment option for this patient population.
Full Text (Upload PDF)
PPT (Upload PPT)